Cognivue Appoints Douglas L. Beck, Au.D., as Vice President of Clinical Sciences
Beck Brings Four Decades of Experience in Audiology and Communication Disorders and Sciences to Cognivue
ROCHESTER, NY (April 12, 2022)—Neuroscience company Cognivue, Inc. has hired Dr. Douglas L. Beck as Vice President of Clinical Sciences. Dr. Beck brings four decades of experience in audiology and communications disorders and sciences to Cognivue and consults, lectures, teaches, volunteers, and writes for multiple audiology, science, medical, and health-related professional organizations globally.
Cognivue President and CEO Tom O’Neill said, “Cognivue is incredibly pleased to welcome Dr. Douglas L. Beck to our team. Doug is an international icon in the hearing care industry and among the most prolific authors in audiology today with more than 208 publications. His outstanding professional reputation and connections in the audiology and ENT fields will no doubt help Cognivue expand its reach in raising awareness of the connection between hearing and cognitive function.”
As Vice President of Clinical Sciences at Cognivue, Dr. Beck is responsible for, among other duties, providing ethical and responsible clinical advice for the use and interpretation of Cognivue products, participating in the development of clinical paradigms, representing Cognivue in a broad arena of clinical fields, and creating manuscripts for peer-reviewed journals and other professional health care publications.
Dr. Douglas L. Beck said, “Hearing care professionals know there is more to auditory perception than loudness measures and pure tones. In fact, some people with mild cognitive impairment or other cognitive issues present with complaints and observations similar to those with hearing loss. Of course, step one is hearing, or simply perceiving sound. However, the end-goal is the ability to listen, to make sense of sound – and that ability is a whole-brain event. I am honored to work with Cognivue to help professionals better understand how the brain perceives, decodes, processes, and makes sense of the world around us. Effective and efficient tools, such as those provided by Cognivue, which facilitate earlier and objective cognitive screenings may provide professionals and patients the opportunity for earlier diagnosis, intervention, and improved outcomes.”
Dr. Beck began his professional career at the House Ear Institute focused on cochlear implant research and intraoperative cranial nerve monitoring. In 1988, he became Director of Audiology at Saint Louis University. In 1996, he co-founded a multi-office dispensing practice in St Louis. He became President and Editor-in-Chief of AudiologyOnline.com and SpeechPathology.com in 1999.
From 2008 through 2015, Dr. Beck served as Web Content Editor for the American Academy of Audiology. In 2016, he was appointed Senior Editor for Clinical Research at the Hearing Review and was appointed Adjunct Clinical Professor of Communication Disorders and Sciences at State University of New York at Buffalo.
In August 2005, Dr. Beck joined Oticon Inc. and in 2019 was appointed Vice President of Academic Sciences. Dr. Beck retired from Oticon in March 2022.
About Cognivue, Inc.
Cognivue, Inc. is a world-class neuroscience company focusing on cognitive health with the world’s first FDA-cleared computerized test of cognitive function. The Cognivue device and technology are based on years of research that uses adaptive psychophysics to focus on cortical information processing by testing key cognitive domains. The technology significantly improves the ability of healthcare providers to implement a personalized assessment of cognitive function in a wide variety of care settings. The company is elevating the gold standard of cognitive health assessment and empowering the healthcare community to monitor, identify and act on early detection of cognitive health concerns. For more information, call (585) 203-1969 or visit cognivue.com.
Media Contact:
Dan Smith
McDougall Communications for Cognivue, Inc.
(585) 434-2154
